Effects of different doses of hyperbaric oxygen on cisplatin-induced nephrotoxicity.
Cisplatin, an effective antineoplastic agent, frequently induces acute renal failure in animals and humans. Hyperbaric oxygen (HBO) has been shown to prevent cisplatin-induced nephrotoxicity in rats. This study investigated the effect of two different HBO regimes on renal functions, oxidative stress, and histopathological changes in rat kidneys after cisplatin treatment. Wistar rats were divided into five groups: control, HBO, cisplatin, cisplatin plus once daily HBO, and cisplatin plus twice daily HBO. Cisplatin was given as a single intraperitoneal dose of 6 mg/kg, and HBO was applied for 60 min at 2.5 atm for six days. HBO alone did not alter any biochemical parameters or histopathological findings compared with the control group. Cisplatin increased serum urea and creatinine levels and caused severe histopathological injury. In addition, cisplatin increased lipid peroxidation and impaired superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities in kidney tissue. Once daily HBO after cisplatin treatment slightly reduced serum urea and creatinine levels and attenuated histopathological injury. HBO also reduced lipid peroxidation and increased SOD and GSH-Px activities significantly. Although twice daily HBO was determined to be more effective than once daily HBO on oxidative stress parameters, it increased serum creatinine levels and histopathological injury compared with the cisplatin group. It was concluded that HBO alone does not induce nephrotoxicity and oxidative stress in rat kidneys; once daily HBO may prevent cisplatin-induced nephrotoxicity, an effect that is partially mediated by the modification of oxidant/antioxidant systems in the kidneys; and twice daily HBO potentiates cisplatin nephrotoxicity by a ROS-independent mechanism.
Aydinoz
Secil
S
Department of Pediatrics, Gulhane Military Medical Academy, Haydarpasa Teaching Hospital, Uskudar, Istanbul, Turkey. saydinoz@yahoo.com
Uzun
Gunalp
G
Cermik
Hakan
H
Atasoyu
Enes Murat
EM
Yildiz
Senol
S
Karagoz
Bulent
B
Evrenkaya
Rifki
R
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000378:metabolism / Q000628:therapy*; D000704:Analysis of Variance; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D002945:Cisplatin / Q000009:adverse effects*; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005979:Glutathione Peroxidase / Q000187:drug effects / Q000378:metabolism; D006931:Hyperbaric Oxygenation; D007677:Kidney Function Tests; D015227:Lipid Peroxidation / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010100:Oxygen / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000187:drug effects / Q000378:metabolism; D014508:Urea / Q000097:blood; D015431:Weight Loss / Q000187:drug effects
D000970:Antineoplastic Agents; D015415:Biomarkers; D014508:Urea; D003404:Creatinine; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D002945:Cisplatin; D010100:Oxygen